Table 1. Clinical and demographic characteristics of 4824 patients with Atrial Fibrillation.
| AF (n = 4824) | ||
|---|---|---|
| Age, mean(SD) | 67 | (13) |
| Female, n(%) | 1685 | (34.93%) |
| Medical history | ||
| Hypertension, n(%) | 1886 | (39.10%) |
| CAD, n(%) | 1403 | (29.08%) |
| Diabetic, n(%) | 667 | (13.83%) |
| RHD, n(%) | 336 | (6.97%) |
| Renal dysfunction, n(%) | 216 | (4.50%) |
| HF, n(%) | 151 | (3.13%) |
| Dilated cardiomyopathy, n(%) | 108 | (2.24%) |
| COPD, n(%) | 103 | (2.14%) |
| Anemia, n(%) | 77 | (1.60%) |
| Vascular disease, n(%) | 58 | (1.20%) |
| Liver dysfunction, n(%) | 50 | (1.04%) |
| Hypertrophy cardiomyopathy, n(%) | 32 | (0.66%) |
| CHADS2 scores, median(quartile) | 1 | (0–2) |
| CHA2DS2-VASc scores, median(quartile) | 2 | (1–3) |
| Drugs | ||
| ACEI/ARB | 707 | (14.66%) |
| Beta blocker | 1072 | (22.22%) |
| Statin | 866 | (17.95%) |
| Other lipid control drug | 50 | (1.04%) |
| Digoxin | 17 | (0.35%) |
| Amiodarone | 349 | (7.23%) |
| Propafenone | 166 | (3.44%) |
| Diuretic | 532 | (11.03%) |
| CCB | 412 | (8.54%) |
| Nitrates | 88 | (1.82%) |
| Insulin | 66 | (1.37%) |
| Sulfonylureas | 44 | (0.91%) |
| Biguanides | 131 | (2.72%) |
| Proton pump inhibitors, PPI | 251 | (5.20%) |
| Nicorandil | 31 | (0.64%) |
| Aspirin | 1022 | (21.19%) |
| Clopidogrel | 345 | (7.15%) |
| Ticagrelor | 13 | (0.27%) |
| Prasugrel | 1 | (0.02%) |
| Warfarin | 450 | (9.33%) |
| Dabigatran | 21 | (0.44%) |
| Rivaroxaban | 10 | (0.21%) |
*CAD: coronary artery disease. RHD: rheumatic heart disease. HF: heart failure. COPD: chronic obstructive pulmonary disease. Vascular disease: carotid atherosclerosis, peripheral vascular disease, vascular amyloidosis, vascular dementia. ACEI/ARB: angiotensin-converting-enzyme inhibitor, angiotensin receptor blockers. CCB: calcium channel blockers.